Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing

D David A. Barrios (1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) S Shihui Guo (1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) M Matthew Powers (2PlateletDiagnostics, LLC, Watertown, MA) S Secil Koseoglu (1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) S Sabrina Zerbey (3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA) R Roosevelt Lu (3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA) A Alexander Cermak (3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA) C Caroline Vayne (4Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France) S Somal Khan (1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) O Omozuanvbo Aisiku (2PlateletDiagnostics, LLC, Watertown, MA) A Arielle Urman (3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA) J Joseph Thomas (3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA) R Rushad Patell (1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA) J Jeffrey I. Zwicker (5Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY) R Robert Flaumenhaft

Abstract

Abstract Dynamin-related protein 1 (Drp1) is an abundant platelet protein best known for its function in mitochondrial fission. However, little is known about how Drp1 is controlled during platelet activation. While evaluating signaling pathways leading to phosphorylation of Drp1 in platelets, we identified a phosphorylation network wherein activation of G protein–coupled receptors or immunoreceptor tyrosine-based activation motif (ITAM)/hemITAM receptors resulted in phosphorylation of Ser616-Drp1 via p38. These signaling mechanisms were reinforced by ADP- and thromboxane A2 (TxA2)-mediated amplification pathways. In contrast, exposure of platelets to pacifying agents such as prostaglandin E1 or nitric oxide resulted in Ser637-Drp1 phosphorylation by cyclic nucleotide-dependent protein kinases. This unique circuitry was leveraged to develop immune-based platelet function assays, enabling enzyme-linked immunosorbent assay and lateral flow assay formats. Compared with standard platelet function assays, Drp1 phosphorylation remained robust in whole blood samples following agitation or extended incubation, and samples could be frozen for batching. As proof of principle for antiplatelet testing, phospho-Drp1 measurements were obtained at baseline, during a week of aspirin or clopidogrel exposure, and during a week of washout. Arachidonic acid–induced Ser616-Drp1 phosphorylation following aspirin ingestion demonstrated an enhanced dynamic range with improved linearity relative to light transmission aggregometry and an improved signal-to-noise ratio relative to the VerifyNow aspirin test. Ser637-Drp1 phosphorylation enabled sensitive detection of clopidogrel ingestion. These studies elucidate the unique signaling circuit controlling Drp1 phosphorylation in platelets and validate the approach of using detailed knowledge of platelet signaling pathways to develop high-fidelity immune-based assays to monitor platelet function.

Article Details

Journal Blood
Volume / Issue Vol. 148, Issue 4
Published July 23, 2026
Pages 477-490
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (15)

D

David A. Barrios

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

S

Shihui Guo

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

M

Matthew Powers

2PlateletDiagnostics, LLC, Watertown, MA

S

Secil Koseoglu

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

S

Sabrina Zerbey

3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA

R

Roosevelt Lu

3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA

A

Alexander Cermak

3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA

C

Caroline Vayne

4Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France

S

Somal Khan

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

O

Omozuanvbo Aisiku

2PlateletDiagnostics, LLC, Watertown, MA

A

Arielle Urman

3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA

J

Joseph Thomas

3Cancer Clinical Trials Office, Beth Israel Deaconess Medical Center, Boston, MA

R

Rushad Patell

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

J

Jeffrey I. Zwicker

5Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY

R

Robert Flaumenhaft